Science Publications & Talks

Shortcuts 2018 2017 2016 2015 2013 2012 2011

2018

• Presentation

  Johnston, PV, Duckers, HJ, Raval, AN, Cook, TD, Traverse, JH, Abraham, WT, Altman, PA, Pepine, CJ. The CardiAMPHeart Failure Trial: Efficacy Outcomes from Roll-In Phase. Presented at the Annual Scientific Sessions of the American Heart Association, November 12, 2018.

• Paper

  Johnston P, Duckers H, Raval A, Cook TD, Pepine CJ. Not all stem cells are created equal: The case for prospective assessment of stem cell potency in the CardiAMP Heart Failure Trial. Circ Res 2018;123:944–46.

• Presentation

  Johnston PV, Duckers HJ, Raval AN, Cook T, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP™ Heart Failure Clinical Trial First Results from the Unblinded Roll-In Phase. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.

• Presentation

  Duckers, HJ, Ravel AN, Pepine, CJ, Johnston, PV, Traverse JH, Emery, J, Miller, L, Abraham, WT, Altman, PA. Performance of Helix transendocardial biotherapeutic delivery system after 300 cases. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.

• Poster

  Pepine, CJ, Raval, AN, Johnston, PV, Traverse, JH, Abraham, WT, Altman, PA. CardiAMP™ Heart Failure Trial Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure. Presented at Annual Meeting of Heart Failure Society of America. September 15-18, 2018.

• Paper

  Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design, American Heart Journal, (In Press) April 2018.

2017

• Paper

  Mitsutake Y, Pyum WB, Rouy D, et al. Improvement of local cell delivery using Helix Transendocardial Delivery Catheter in a porcine heart. Int Heart J. 2017.

2016

• Paper

  Bergmann MW, Heeger C, Jaquet K, Boosfeld C et al. Early Transendocardial Autologous Bone Marrow Injection Of Bone Marrow Derived Mononuclear Cells Following Ischemic Myocardial Events (the Alster - Helix Phase I Study), CRT 2016.

2015

• Paper

  Wong Po Foo C, Rouy D, Hare JM, et al. The transendocardial autologous cells in ischemic heart failure trial bone marrow mononuclear cells (TAC-HFT-BMC) randomized placebo controlled blinded study, Regenerative Medicine 2015, 10(7s), S169.

2013

• Paper

  Heldman AW,  DiFede DL,  Fishman JE et al.  Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy The TAC-HFT Randomized Trial JAMA. 2013.282909.

2012

• Paper

  Hare JM, Fishman, JE, Gerstenblith G, et al. Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy, The POSEIDON Randomized Trial, JAMA. 2012;308(22).

2011

• Paper

  de la Fuente LM, Stertzer SH, Argentieri J, Transendocardial Autologous Bone Marrow in Myocardial Infarction Induced Heart Failure, Two Year Follow up in an Open Label Phase I Study, Eurointervention 2011; 7:805-812.